Clinical studies on Sunitinib (Sutent), Sorafenib (Nexavar) and mTOR inhibitors, small molecular VEGFR inhibitors used in advanced stage ccRCC, have rarely shown complete response to treatment [47]. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.